Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.
about
Cell culture-based influenza vaccines: A necessary and indispensable investment for the futureImmunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strainsContinuous cell lines as a production system for influenza vaccines.New technologies for influenza vaccines.Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).Traditional and new influenza vaccinesImmunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.The future of cell culture-based influenza vaccine production.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Immunological assessment of influenza vaccines and immune correlates of protection.Flucelvax (Optaflu) for seasonal influenza.Influenza vaccines: Evaluation of the safety profile.
P2860
Q28084739-76F31DED-D767-4519-99F4-7B08F04DAEB1Q30355688-E35CE718-BB54-4383-829E-9F669E38D934Q30374968-8BF4295E-2BFC-4D51-B420-A6A6621BC192Q30382947-15E1E68A-F991-4ED8-A0C4-201A64C84992Q30411859-BB0C74E7-A19D-4A93-93ED-203588DEDE71Q30419591-B18E519C-BAA4-4282-B51F-DD5994D4AF2CQ30420569-31544BA1-F761-4D04-A16D-1901304AE8ABQ34984192-2651D3DE-EE64-4F85-AAE1-419BCDF23436Q37035833-244A55FD-0DA6-42E3-B117-623E8F4A5112Q37231850-C42BC8FB-851E-4DBA-A9D9-92CF76928FB0Q37694883-82233A2D-C4A9-4981-A23D-2F7B4174B2ABQ37919896-66B6F0CF-C4CD-4CD8-9273-9BB3C9BE919AQ38045920-A9564C5C-758E-4950-8CC7-DBFE5C12B749Q38105339-FBD36CC6-D82D-4DB1-A6C7-CB81FE13170AQ38476345-89B53FA5-EBB5-495F-9804-D873739EA817Q49345779-433D444C-87F6-48ED-A730-F379F66457E5
P2860
Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Safety, tolerability and immun ...... I and Phase II clinical trial.
@en
Safety, tolerability and immun ...... I and Phase II clinical trial.
@nl
type
label
Safety, tolerability and immun ...... I and Phase II clinical trial.
@en
Safety, tolerability and immun ...... I and Phase II clinical trial.
@nl
prefLabel
Safety, tolerability and immun ...... I and Phase II clinical trial.
@en
Safety, tolerability and immun ...... I and Phase II clinical trial.
@nl
P2093
P1433
P1476
Safety, tolerability and immun ...... I and Phase II clinical trial
@en
P2093
P304
P356
10.1016/J.VACCINE.2008.11.003
P407
P577
2008-11-21T00:00:00Z